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S-adenosyl-L-methionine decarboxylase (AdoMetDC) in the polyamine biosynthesis pathway has been
identiﬁed as a suitable drug target in Plasmodium falciparum parasites, which causes the most lethal form
of malaria. Derivatives of an irreversible inhibitor of this enzyme, 50-{[(Z)-4-amino-2-butenyl]methyl-
amino}-50-deoxyadenosine (MDL73811), have been developed with improved pharmacokinetic proﬁles
and activity against related parasites, Trypanosoma brucei. Here, these derivatives were assayed for
inhibition of AdoMetDC from P. falciparum parasites and the methylated derivative, 8-methyl-50-{[(Z)-
4-aminobut-2-enyl]methylamino}-50-deoxyadenosine (Genz-644131) was shown to be the most active.
The in vitro efﬁcacy of Genz-644131 was markedly increased by nanoencapsulation in immunoliposomes,
which speciﬁcally targeted intraerythrocytic P. falciparum parasites.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Polyamines (putrescine, spermidine and spermine) are critical
components of cell growth and division, particularly in rapidly
proliferating cells that include cancerous cells and numerousparasites (Casero and Marton, 2007; Heby et al., 2007). A number
of enzymes in the biosynthesis of polyamines have been vali-
dated as suitable drug targets including ornithine decarboxylase
(ODC) (Pegg, 2006) and S-adenosyl-L-methionine decarboxylase
(AdoMetDC) (Pegg, 2009) as the two major enzymatic activities.
Protozoan infections resulting in human parasitic diseases such
as African sleeping sickness (caused by subspecies of Trypanosoma
brucei), Chagas disease (Trypanosoma cruzi), leishmaniasis
(Leishmania spp) and malaria (Plasmodium spp) are highly reliant
on substantial amounts of polyamines for development and prolif-
eration (Heby et al., 2003; Birkholtz et al., 2011). Of these diseases,
malaria has a high disease incidence in most tropical regions of the
world, with Plasmodium falciparum parasites being the most lethal.
AdoMetDC catalyses a chokepoint reaction to produce decar-
boxylated S-adenosyl-L-methionine (dcAdoMet) that is exclusively
used for polyamine biosynthesis. The irreversible AdoMetDC inhib-
itor, 50-{[(Z)-4-amino-2-butenyl]methylamino}-50-deoxyadenosine
(MDL73811), is 100-fold more effective than the ODC inhibitor,
DL-a-diﬂuoromethylornithine (DFMO), in curing murine T. b. brucei
and T. b. rhodesiense infections. Treatment of T. brucei parasites
D. le Roux et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 28–36 29with MDL73811 causes an intracellular hypermethylated state due
to accumulation of S-adenosyl-L-methionine (Byers et al., 1991) in
addition to the detrimental depletion of trypanothione (the princi-
pal polyamine-dependent thiol in trypanosomes) (Yarlett et al.,
1991; Willert and Phillips, 2008). AdoMetDC is considered an
attractive drug target in P. falciparum parasites due to its unique
association with ODC in a heterotetrameric bifunctional protein
complex, PfAdoMetDC/ODC (van Brummelen et al., 2008; Birkholtz
et al., 2011; Williams et al., 2011). MDL73811 inhibits in vitro
intraerythrocytic P. falciparum parasite proliferation (Wright
et al., 1991; Das Gupta et al., 2005), however, this does not result
in a hypermethylated state but only depletes intracellular poly-
amine levels, leading to cellular cytostasis (Wallace et al., 2003;
van Brummelen et al., 2008; Birkholtz et al., 2011).
MDL73811, however, is not clinically useful against parasitic
infectious due to poor blood brain barrier penetration, a short plas-
ma half-life, poor oral bioavailability and limited metabolic activity
(Wright et al., 1991; Das Gupta et al., 2005; Barker et al., 2009).
Structure-guided design of MDL73811 derivatives, modiﬁed on
the ribose and purine moieties through addition of halogens and
methyl groups, resulted in a series of compounds with improved
ADME toxicity proﬁles. These included improved aqueous solubil-
ity, decreased rates of hepatocyte and microsome clearance, mini-
mal CYP inhibition and half the plasma protein binding capacity
compared to MDL73811 (Bacchi et al., 2009; Barker et al., 2009;
Hirth et al., 2009). Methylation of position 8 of the adenine group
resulting in 8-methyl-50-{[(Z)-4-aminobut-2-enyl]methylamino}-
50-deoxyadenosine (Genz-644131) displayed an increased inhibi-
tory potency against heterologous TbAdoMetDC. This compound
showed improved cellular toxicity against different T. brucei para-
site strains, with a longer plasma half-life and improved blood
brain barrier penetration in in vivomice (Bacchi et al., 2009; Barker
et al., 2009). Here, the MDL73811 derivatives were assessed for
inhibitory activity against heterologous PfAdoMetDC as well as
for inhibition of intraerythrocytic P. falciparum parasite prolifera-
tion in vitro.2. Methods and materials
2.1. MDL73811 and derivatives
MDL73811 (50-{[(Z)-4-amino-2-butenyl]methylamino}-50-deoxy-
adenosine), Genz-644131 (8-methyl-50-{[(Z)-4-amino-2-butenyl]
methylamino}-50-deoxyadenosine), Genz-644043 (20-ﬂuoro-50-{[(Z)-
4-amino-2-butenyl]methylamino}-50-deoxyadenosine), and Genz-
644053 (2-chloro-50-{[(Z)-4-amino-2-butenyl]
methylamino}-50-deoxyadenosine) (Table 1) were synthesised by
the Genzyme Corporation (www.genzyme.com, 2013; Hirth et al.,
2009).2.2. Recombinant PfAdoMetDC enzyme inhibition assays
The monofunctional form of PfAdoMetDC (harmonised gene
construct) as well as bifunctional PfAdoMetDC/ODC were heterolo-
gously expressed in Escherichia coli BL21 Star™ (DE3) cells and
puriﬁed via Strep-tag afﬁnity chromatography as previously de-
scribed (Birkholtz et al., 2004; Williams et al., 2011). To determine
the enzyme inhibition activity of the MDL73811 derivatives, an
isotope-based bioassay that measures the release of radiolabeled
CO2 (Birkholtz et al., 2004; Williams et al., 2011) was performed
with 5 lg of either monofunctional PfAdoMetDC or bifunctional
PfAdoMetDC/ODC in the presence of 1 lM of each derivative.
Results were normalised to the speciﬁc activity (nmol/min/mg)
of an uninhibited control to determine % inhibition.2.3. Determination of the inhibition constant of Genz-644131 against
PfAdoMetDC
The apparent inhibition constant (Kiapp) of Genz-644131 was
determined with Kitz and Wilson time dependent enzyme kinetics
for irreversible inhibitors as described (Kitz and Wilson, 1962).
Using the isotope-based bioassay described above, residual enzyme
activitywasmeasured followingpre-incubation (37 C) atﬁxed time
intervals (2, 4 and 6 min) with varying inhibitor concentrations
(0.02, 0.05 and 0.1 lM) and 1 lg of either monofunctional PfAdo-
MetDC or bifunctional PfAdoMetDC/ODC, each in duplicate. The
reciprocal of the slope in the primary graph (kapp) was plotted
against the reciprocalof the inhibitor concentrations toyield the sec-
ondary plot, fromwhich the kinact and theKiapp valueswere derived.
2.4. Homology modelling and conformational analysis
P. falciparum and T. brucei homology models were generated
using the human AdoMetDC crystal structure (PDBid 3DZ2) as
template similar to a previously described model (Wells et al.,
2006). Molecular shape-based alignment between MDL73811
derivatives and the homology model was performed with vROCS
(v3.1.0 OpenEyeScientiﬁc Software, Inc., Santa Fe, NM, USA,
www.eyesopen.com, 2010) (Supplemental data; Fig. S1 and
Table S1). Conformational analysis was performed using Confor-
mation Search and the Minimisation module of Discovery Studio
3.0 suite (Accelrys, Inc.). Detailed methods for homology model-
ling, molecular shape based alignment and conformational analysis
are provided in Supplemental data, S1.
2.5. In vitro cultivation of intraerythrocytic P. falciparum parasites and
IC50 determination of MDL73811 derivatives
Intraerythrocytic P. falciparum parasites (strain 3D7; chloro-
quine sensitive) were maintained in P. falciparum culture media
as described (Verlinden et al., 2011). Intraerythrocytic parasites
were synchronised to a 95% ring stage population with a 5% sorbi-
tol solution. The effect of MDL73811 derivatives on the prolifera-
tion of intraerythrocytic P. falciparum parasites at 37 C for 96 h
was determined using a SYBR Green I-based ﬂuorescence assay
as described (Verlinden et al., 2011). MDL73811 and Genz-
644131 were dissolved in 1xPBS and Genz-644043 and Genz-
644053 in DMSO and incubated with ring stage intraerythrocytic
P. falciparum parasites (1% parasitaemia, 1% haematocrit) at spe-
ciﬁc concentrations, serially diluted 2-fold in culture medium (ﬁnal
0.1% (v/v)) non-lethal DMSO concentration (Grobusch et al., 1998).
Sigmoidal dose–response curves were ﬁtted to the data using Sig-
maPlot 11.0 with non-linear regression yielding the IC50 values
(concentration at which 50% inhibition of parasite proliferation
was observed).
2.6. Determining parasite recovery following Genz-644131 inhibition
The ability of the products of polyamine metabolism to rescue
parasites from the inhibitory effect of Genz-644131 was deter-
mined. Ring stage intraerythrocytic P. falciparum parasites
(1% parasitaemia, 1% haematocrit) were treated with Genz-
644131 (2xIC50) in the presence of exogenous spermidine trichlo-
ride (non-toxic concentration, 250 lM, results not shown) and
500 lM of the polyamine oxidase inhibitor, aminoguanidine
(Niemand et al., 2013), for 96 h at 37 C and parasite proliferation
determined with a SYBR Green I-based assay (Stjernborg and
Persson, 1993; Lee and Sayre, 1998).
Subsequently, to determine the ability of ring stage intraerythr-
ocytic P. falciparum parasites (1% parasitaemia, 1% haematocrit) to
recover after Genz-644131 treatment, the latter was withdrawn
Table 1
Conformational search analysis of MDL73811 and its derivatives.
Lowest overall
energy
conformation#
Lowest syn energy
conformation#
Number of
conformations
generated#
Bioactive syn
conformational
number*, #
MDL73811
50-{[(Z)-4-amino-2-butenyl]methylamino}-50-deoxyadenosine N
NN
N
NH2
O
HO OH
N
NH2
131.6 124.0 200 22
Genz-
6441318-methyl-50-{[(Z)-4-amino-2-butenyl]methylamino}-50-
deoxyadenosine
N
NN
N
NH2
O
HO OH
N
NH2
132.9 130.7 207 7
Genz-
64404320-ﬂuoro-50-{[(Z)-4-amino-2-butenyl]methylamino}-50-
deoxyadenosine
N
NN
N
NH2
O
F OH
N
NH2
131.0 117.8 193 106
Genz-
6440532-chloro-50-{[(Z)-4-amino-2-butenyl]methylamino}-50-
deoxyadenosine
N
NN
N
NH2
O
HO OH
N
NH2
C l
136.0 127.8 209 64
# All energies are given in kcal/mol.
* Generated conformations were ranked from the lowest to highest energy i.e. the bioactive syn conformation of Genz-644131 was ranked the 7th lowest energy confor-
mation from 207 conformations generated.
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and subsequently resuspended in normal culture media. Samples
were removed at 12 h intervals over 96 h and DNA content was
determined for the treated, untreated and the Genz-644131 with-
drawn parasite populations using a SYBR Green I-based assay.
2.7. Spermidine uptake in intraerythrocytic P. falciparum parasites
Intraerythrocytic P. falciparum parasites were puriﬁed toP 95%
parasitaemia with magnetic separation (Trang et al., 2004; Teng
et al., 2009). [3H]spermidine uptake was initiated by combining
equal volumes of cell suspension and radiolabelled solution
(1 lCi/ml [3H]spermidine at 5 nm extracellular concentration,
PerkinElmer, in 125 mM NaCl, 5 mM KCl, 20 mM glucose, 25 mM
HEPES and 1 mM MgCl2, pH 7.1). At predetermined time intervals
following incubation at 37 C, the reactions were terminated by
dibutyl phthalate sedimentation. A 10 ll sample of the aqueous
phase was transferred to a scintillation vial to determine the extra-
cellular concentration of [3H]spermidine. The remaining cell pellet
was lysed with 0.1% (v/v) Triton X-100, the proteins precipitated
with 5% w/v trichloroacetic acid and cell debris (including mem-
brane fractions) removed with centrifugation before measuring
the radioactivity present in the aqueous supernatant. The rapid ini-
tial association of radiolabel with the cells, due to polyamines
trapped in the extracellular space as well as adhering to the cell
surface was determined and subtracted from the total measured
radioactivity (cmp’s) to determine the intracellular concentration
of polyamines. The data are given as a distribution ratio of intracel-
lular to extracellular spermidine (Saliba et al., 1998).
2.8. Comparative IC50 determination of Genz-644131 incorporated
with Pheriod

technology
A micellular formulation of a nanoparticle structure, Pheroid

,
consisting mainly of 43.8% plant and essential ethylated and PEGy-
lated polyunsaturated fatty acids, was prepared in incomplete
RPMI 1640 medium as described (Grobler et al., 2008; Steynet al., 2011). The suspension was subsequently ﬁltered (0.22 lm),
diluted 50 with sterile water and homogenised with Genz-
644131 powder to yield an encapsulated suspension with a ﬁnal
compound concentration of 23.75 mM. The encapsulation efﬁ-
ciency of Pheroid

was analysed with confocal laser scanning
microscopy (Grobler et al., 2007). Subsequently, ring stage intra-
erythrocytic P. falciparum parasites (1% parasitaemia, 1% haemato-
crit) were treated with Genz-644131 encapsulated Pheroid

at a
20-fold dilution (24 lM initial starting concentration) and incu-
bated for 96 h at 37 C. Parasite proliferation of cell suspensions
treated with Genz-644131 encapsulated into Pheroid

was deter-
mined, and normalised against non Genz-644131 encapsulating
Pheroid

in order to derive the IC50 value using a SYBR Green
I-based assay.
2.9. Comparative IC50 determination of Genz-644131 with
immunoliposomes
Immunoliposomes were prepared by the lipid ﬁlm hydration
method (MacDonald et al., 1991) and covalently functionalisedwith
IgG antibody fragments prepared speciﬁcally for intraerythrocytic P.
falciparumparasites (Urbánet al., 2011a). For encapsulationofGenz-
644131, 1.74 mg of the compound was incorporated into a 1.5 ml
immunoliposome suspension to give a ﬁnal concentration of encap-
sulated Genz-6644131 at 30 lM (10% encapsulation efﬁciency).
Ring stage intraerythrocytic P. falciparum parasites (1% parasita-
emia, 1% haematocrit) were treated with Genz-644131 encapsu-
lated immunoliposomes at a 50-fold dilution (0.6 lM starting
concentration) and incubated for 96 h at 37 C. Parasite proliferation
of cell suspensions treated with Genz-644131 encapsulated into
immunoliposomes was determined as described above.
2.10. Statistical analyses
All data are representative of at least three independent biolog-
ical experiments (nP 3), each performed in triplicate. Statistical
analysis was performed using either paired or unpaired Student’s
D. le Roux et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 28–36 31t-tests. Data were analysed using GraphPad Prism 5.0 or SigmaPlot
11.0.3. Results
3.1. Inhibitory effect of MDL73811 derivatives on heterologous
monofunctional PfAdoMetDC and bifunctional PfAdoMetDC/ODC
MDL73811 and Genz-644131 showed the highest percentage
inhibition of monofunctional PfAdoMetDC at 98% and 100%,
respectively (n = 3, P < 0.01, paired Student’s t-test) (Fig. 1). TheFig. 1. The inhibitory activities of MDL73811 derivatives against monofunctional
PfAdoMetDC (grey) and the PfAdoMetDC domain of bifunctional PfAdoMetDC/ODC
(black). MDL73811 and the three derivatives (1 lM) were incubated with either
5 lg monofunctional PfAdoMetDC or bifunctional PfAdoMetDC/ODC for 30 min at
37 C. Speciﬁc activity (nmol/min/mg) of the monofunctional and bifunctional
PfAdoMetDC domains were normalised against the uninhibited enzymes. Data are
representative of three independent experiments performed in triplicate, ±SEM.
⁄⁄P < 0.01, paired Student’s t-test. Where not shown, the error bars fall within the
symbols.
Fig. 2. Enzyme kinetics of Genz-644131 against monofunctional and bifunctional PfA
Genz-644131 against monofunctional (A and B) and bifunctional PfAdoMetDC (C and
pre-incubation with Genz-644131 at 0.02 (circles), 0.05 (squares) or 0.1 lM (triangles) co
at a speciﬁc inhibitor concentration was plotted against the pre-incubation time points u
(A and C) was plotted against the reciprocal of the speciﬁc inhibitor concentrations using
the Kiapp (slope multiplied by kinact) were derived (Kitz and Wilson, 1962). Data are rep
values fell into the 95% conﬁdence interval of the mean. Where not shown, the error bainhibition of the PfAdoMetDC domain of heterologous bifunctional
PfAdoMetDC/ODC was similar at 96% and 98%, respectively (n = 3,
P < 0.01, paired Student’s t-test) (Fig. 1). By contrast, Genz-
644043 only inhibited monofunctional PfAdoMetDC by 57%
(n = 3, P = 0.14, paired Student’s t-test) whereas Genz-644053
had no inhibitory effect (Fig. 1).
The activity of PfAdoMetDC decreased in a concentration
dependent manner following pre-incubation with Genz-644131
for both monofunctional and bifunctional forms of the protein
(Fig. 2A and C). A non-signiﬁcant increase in the Kiapp value of
0.36 ± 0.10 lM (n = 3, P > 0.05, unpaired Student’s t-test) was
determined for Genz-644131 on monofunctional PfAdoMetDC
(Fig. 2B) compared to 0.22 ± 0.09 lM for MDL73811 (results not
shown). However, there was a signiﬁcant difference in the inhibi-
tion of bifunctional PfAdoMetDC/ODC by Genz-644131 (Kiapp at
0.18 ± 0.02 lM (Fig. 2D) compared to MDL73811 (0.53 ± 0.09 lM,
results not shown) (n = 3, P = 0.02, unpaired Student’s t-test).
The efﬁciency of inactivation (depicted by the kinact/Kiapp ratio)
of MDL73811 compared to Genz-644131 against monofunctional
PfAdoMetDC was not signiﬁcantly different at 1.91 and 1.17 lM1 -
min1, respectively. However, the inactivation efﬁciency for
Genz-644131 against the PfAdoMetDC domain of bifunctional
PfAdoMetDC/ODC is 1.6-fold higher (kinact/Kiapp = 3.50 lM1
min1) compared to MDL73811 (kinact/Kiapp = 2.19 lM1 min1).
Moreover, there was a 3-fold increase in the inactivation efﬁ-
ciency of Genz-644131 against bifunctional PfAdoMetDC/ODC
compared to monofunctional PfAdoMetDC (kinact/Kiapp ratios of
3.50 vs. 1.17 lM1 min1), respectively. Genz-644131 seems to
therefore be a more effective inhibitor of PfAdoMetDC compared
to MDL73811, with marked preference for the protein when found
in its native conformation in bifunctional PfAdoMetDC/ODC.
Due to the observed differences in the inhibition of MDL73811
and its derivatives against PfAdoMetDC, the binding capacity of
these compounds to PfAdoMetDC was analysed in silico. Previously,
it was shown that purine nucleoside AdoMetDC inhibitors adoptdoMetDC. Kitz-Wilson inhibition kinetics was used to determine the Kiapp for
D). Percentage activity was determined from residual enzyme activity, following
ncentrations ([I]) at speciﬁc time intervals (0–6 min) (Et). The ln(Et/E0) of the activity
sing non-linear regression. The reciprocal of the slopes (1/kapp) of the primary plots
non-linear regression (B and D), fromwhich the kinact (inverse of the y-intercept) and
resentative of three independent experiments performed in triplicate, ±SEM and all
rs fall within the symbols.
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tors does not only affect protein ligand interactions but also alter
conformational preferences (Tolbert et al., 2001) (Supplemental
data S1). MDL73811 has an energy difference of 7.6 kcal/mol be-
tween the lowest energy conformation and its bioactive syn con-
formation (Table 1). However, the 8-methyl substitution on the
purine rings of MDL73811, yielding Genz-644131, increases the
conformational preference for the bioactive syn conformation of
the latter (energy difference equal to 2.2 kcal/mol, Table 1). By con-
trast, the energy differences for both the halogen substituted Genz-
644043 and Genz-644053 derivatives were higher, with the latter
also showing a distorted N-(Z)-4-aminobutenyl-N-methyl tail con-
formation due to interference of the chlorine substitution at posi-
tion 2 of the purine ring (Supplemental data S1).
The selected binding pose of Genz-644131 (Fig. 3A) shows sim-
ilar interactions to other AdoMetDC substrate analogues (Fig. 3B)
(McCloskey et al., 2009). Moreover, conformational search analysis
of the N-(Z)-4-aminobutenyl-N-methyl tail of Genz-644131
showed that the lowest absolute energy of the Genz-644131 syn
conformation is reached when the tail assumes the predicted bind-
ing conformation (-126.9 kcal/mol) (Fig. 3C). Notably, the 8-methyl
substitution on the purine ring does not show any steric hindrance
within the protein active site and therefore would not negatively
affect ligand binding.3.2. Genz-644131 is active against in vitro intraerythrocytic P.
falciparum parasites
The IC50 of the MDL73811 derivatives was determined on intra-
erythrocytic P. falciparum parasites in vitro (96 h incubation at
37 C). Treatment of intraerythrocytic P. falciparum parasites with
Genz-644131 resulted in a signiﬁcant, 2-fold decrease in the IC50
compared to MDL73811 (IC50 = 0.97 ± 0.06 lM vs. 2.21 ± 0.07 lM,
n = 5, P < 0.01, unpaired Student’s t-test). The IC50 values of Genz-
644043 and Genz-644053 against intraerythrocytic P. falciparum
parasites were signiﬁcantly higher (25.6 ± 8.4 and 22.4 ± 7.5 lM;
n = 4, P > 0.05, unpaired Student’s t-test) than that of the parent
compound, MDL73811.Phe415  
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Fig. 3. A predicted binding pose for Genz-644131 to PfAdoMetDC highlighting conserve
PfAdoMetDC bound with Genz-644131 in the active site. The ribbon representing the b-
residues. Likewise, the a-chain ribbon is coloured in a lighter shade. (B) The interacting
bonds formed between the protein and ligand. (C) Representation of the systematic conf
energy conformations in yellow. (For interpretation of the references to colour in this ﬁThe ability of exogenous polyamines to rescue the inhibitory
effect of Genz-644131 on intraerythrocytic P. falciparum parasites
was established by determining the IC50 of Genz-644131 in the
presence and absence of exogenous spermidine (250 lM). No
signiﬁcant change in the IC50 value of Genz-644131 in the
presence (IC50 = 0.94 ± 0.03 lM) or absence (IC50 = 0.97 ± 0.06 lM)
of spermidine (n = 3, P = 0.89, paired Student’s t-test) was observed
(Fig. 4A), indicating that spermidine could not antagonise the
inhibitory effect of Genz-644131. However, P. falciparum infected
erythrocytes are capable of taking up exogenous spermidine,
with [3H]spermidine reaching a distribution ratio of 1.4 ± 0.4
(n = 6) following 60 min incubation (Fig. 4B).
The recovery of intraerythrocytic P. falciparum parasites
(1% parasitaemia, 1% haematocrit) after limited exposure to
Genz-644131 (2 IC50) for 24 h was determined after washing
out the compound, followed by additional incubation of parasite
cultures for a further 96 h before measuring DNA content as an
indicator of parasite proliferation. There was a signiﬁcant increase
in DNA levels observed for untreated parasites over the two life-cy-
cles analysed (Fig. 4C). Genz-644131 treated ring-stage intra-
erythrocytic P. falciparum parasites (2 IC50) were able to recover
after 24 h of drug pressure and continue to proliferate following
drug removal (Fig. 4C). However, continuous exposure of intra-
erythrocytic P. falciparum parasites to Genz-644131 (2 IC50) for
96 h resulted in a stage-speciﬁc inhibition of parasite proliferation,
with parasites arrested in the trophozoite stage (24 h post-inva-
sion) within the ﬁrst life-cycle (Fig. 4D).3.3. Effect of Genz-644131 encapsulated in nanovectors on in vitro
antiplasmodial activity
To improve membrane translocation of Genz-644131 and pos-
sibly the in vitro activity against intraerythrocytic P. falciparum
parasites, Genz-644131 was encapsulated into two types of
nanovectors, a submicron micellular emulsion formulation, Phe-
roid

(Grobler et al., 2008), and a parasite targeting immunolipo-
some system (Urbán et al., 2011a). The compound encapsulated
into Pheroid

did not show a signiﬁcant decrease in the in vitro
IC50 (0.97 ± 0.06 lM compared to 0.67 ± 0.29 lM; n = 4, P > 0.05,Phe5 
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Fig. 4. Uptake of [3H]spermidine, with rescue and reversibility of Genz-644131
inhibited intraerythrocytic P. falciparum parasites in vitro. (A) Initial ring stage
intraerythrocytic P. falciparum parasites were treated with Genz-644131 (serial
dilution) alone (squares) or in the presence of 250 lM spermidine (circles, 0.5 lM
aminoguanidine present) for 96 h at 37 C. Parasite proliferation is expressed as a
percentage of untreated parasite proliferation at 100%. Data are representative of
nP 3 independent experiments performed in triplicate, ± SEM. (B) Time course for
the uptake of [3H]spermidine (5 nM extracellular concentration) into intraerythr-
ocytic P. falciparum parasites (circles) at 37 C over 60 min averaged from ﬁve
independent experiments and shown ± SEM. A distribution ratio of 1.4 ± 0.4 was
obtained, where a ratio of 1 indicates that the radiolabelled polyamine has
equilibrated to levels equal to the extracellular levels. (C) Initial ring stage
intraerythrocytic P. falciparum parasites were either treated with Genz-644131
(2  IC50, squares) for 96 h at 37 C or treated with Genz-644131 (2  IC50, triangles)
for 24 h at 37 C before replacing the culture media thereby removing the Genz-
644131 before incubating the parasites for a further 96 h at 37 C. Untreated initial
ring stage intraerythrocytic P. falciparum parasites (circles) incubated at 37 C for
96 h was included as a positive control for parasite proliferation. Samples were
taken every 12 h and DNA content was measured as relative ﬂuorescence units
using SYBR Green I-based assay. Data are representative of nP 3 independent
experiments performed in triplicate, ±SEM. Where not shown, the error bars fall
within the symbol. (D) Morphological monitoring of the stage speciﬁcity of
parasites treated with Genz-644131 (2  IC50), analysing percentage distribution
in each life-cycle stage. Treated parasites indicated that Genz-644131 arrested
parasite development during the trophozoite stage compared to untreated
parasites.
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encapsulated immunoliposomes showed a signiﬁcant 32-fold
decrease in the in vitro IC50 compared to non-encapsulatedGenz-644131 (0.97 ± 0.06 lM vs. 0.031 ± 0.004 lM; n = 3,
P < 0.01, unpaired Student’s t-test) (Fig. 5B).4. Discussion
Polyamine biosynthesis enzymes have been the target of vari-
ous parasitic disease intervention strategies (Birkholtz et al.,
2011) as highlighted by the clinical treatment of T. brucei infections
through DFMO inhibition of ODC activity (Van Nieuwenhove et al.,
1985). Of the other enzymatic activities associated with polyamine
biosynthesis, inhibition of AdoMetDC shows promise as a thera-
peutic target in P. falciparum, with MDL73811 a 1000-fold more
potent against intraerythrocytic P. falciparum parasites compared
to DFMO (Wright et al., 1991). Although MDL73811 is an irrevers-
ible inhibitor of AdoMetDC activity, it has poor drug-like character-
istics for Plasmodium (Wright et al., 1991) and Trypanosoma
parasites (Barker et al., 2009), which led to the synthesis of phar-
macokinetically amenable derivatives. These derivatives of
MDL73811 were used here to determine (1) their efﬁcacy in inhib-
iting the PfAdoMetDC protein and (2) their antiproliferative activ-
ity against intraerythrocytic P. falciparum parasites in vitro.
Several comparisons can be drawn between the treatment of
P. falciparum and T. brucei parasites with the lead derivative, Genz-
644131. Firstly, the AdoMetDC protein from both these parasites
responds similarly to Genz-644131 treatment. PfAdoMetDC has a
near conserved active site compared to AdoMetDC homologues from
human and T. brucei parasites, despite an overall low sequence
identity (21% and 23%, respectively (Wells et al., 2006)). As a result,
MDL73811 inhibits AdoMetDC from both P. falciparum and T. brucei
parasites at comparable levels and in a similar manner as indicated
by their respective micromolar Kiapp values (Bitonti et al., 1990;
Das Gupta et al., 2005; Williams et al., 2011). However,
Genz-644131 potently inhibits monofunctional and bifunctional
PfAdoMetDC similarly to TbAdoMetDC (Barker et al., 2009) with
Kiapp values in the nanomolar range (Barker et al., 2009).
The 1.6-fold decrease in Kiapp between MDL73811 and Genz-
644131 observed for the bifunctional PfAdoMetDC/ODC is ex-
plained by the 8-methyl substitution on the purine ring of Genz-
644131, which promotes the preferred bioactive syn conformation
(Pegg, 2009). However, Genz-644131 is 7-fold less effective in
inhibiting monofunctional PfAdoMetDC compared to the T. brucei
enzyme (kinact/Kiapp ratios of 1.17 lM1 min1 for PfAdoMetDC
compared to 7.78 lM1 min1 for TbAdoMetDC (Barker et al.,
2009)). The association of PfAdoMetDC with ODC in the biologi-
cally relevant bifunctional protein PfAdoMetDC/ODC has been
shown to result in the modulation of plasmodial AdoMetDC activ-
ity (Birkholtz et al., 2011; Williams et al., 2011). Rate-limiting and
equimolar synthesis of putrescine and dcAdoMet by the ODC and
AdoMetDC activities is enabled by a decrease in AdoMetDC activity
when associated in the bifunctional complex with ODC in compar-
ison to its monofunctional PfAdoMetDC form, respectively
(Williams et al., 2011). Here, although comparative inactivation
efﬁciencies are seen for Genz-644131 for the monofunctional and
bifunctional proteins, this inhibitor shows a 3-fold increase in
speciﬁcity and rate of inhibition of the AdoMetDC domain of the
bifunctional protein. This can be attributed to the lower substrate
Km of PfAdoMetDC in the bifunctional protein compared to the
monofunctional protein, which probably reﬂects differences be-
tween active site conformations of these two proteins and conse-
quently, their binding afﬁnities for Genz-644131 (Williams et al.,
2011). Interestingly, the simultaneous inhibition of both activities
of the bifunctional PfAdoMetDC/ODC with Genz-644131 and
DFMO is additive as was also shown for MDL73811 and
DFMO on in vitro P. falciparum parasites (Wright et al., 1991; van
Brummelen et al., 2008) (Supplemental data S2).
Fig. 5. The effect of encapsulation of Genz-644131 in different nanovectors on its in vitro anti-plasmodial activity. Parasite proliferation of ring stage intraerythrocytic
P. falciparum parasites was monitored with a SYBR Green I-based assay over 96 h at 37 C and IC50 determined from dilution series. Dose–response curves for Genz-644131
alone (squares) compared to incorporated into (A) Pheroid

or (B) immunoliposomes (circles). Data are representative in each instance of three independent experiments
performed in triplicate or quadruplicate, ±SEM. Where not shown, the error bars fall within the symbols.
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in vitro antiproliferative efﬁcacy of T. brucei parasites treated with
Genz-644131 compared to MDL73811 (Barker et al., 2009), Genz-
644131 only shows marginal (2-fold) improvement in the in vitro
IC50 against intraerythrocytic P. falciparum parasites. The antipro-
liferative effect observed with Genz-644131 was not plasmodi-
cidal to the parasite, similar to treatment with MDL73811 and
DFMO, with parasite proliferation recovering after limited Genz-
644131 exposure (24 h at 2 IC50). Both MDL73811 and DFMO
treatment result in a cytostatic effect since inhibition is negated
by the uptake of exogenous polyamines (Assaraf et al., 1987;
Das Gupta et al., 2005). Co-treatment of parasites with
MDL73811 and exogenous spermidine did not abolish the inhib-
itory effect of MDL73811 on parasite proliferation, and it was pre-
viously suggested that intraerythrocytic P. falciparum parasites
are incapable of spermidine uptake, since exogenously supplied
putrescine, but not spermidine, was capable of overcoming bio-
synthesis inhibition caused by a variety of inhibitors (Assaraf
et al., 1987; Das Gupta et al., 2005). Likewise, co-treatment of par-
asites with Genz-644131 and exogenous spermidine also did not
abolish the inhibitory effect of Genz-644131 on parasite prolifer-
ation. However, recent work clearly indicates that exogenous
spermidine is taken up by isolated P. falciparum trophozoite-stage
parasites (Niemand et al., 2012). Once inside the infected erythro-
cyte unit, the parasite is able to efﬁciently take up spermidine
across the plasma membrane in a concentration dependent
manner, mediated by an electrogenic process energised by the
parasite’s membrane potential (Niemand et al., 2012). In addi-
tion, here we report that exogenous spermidine is taken up by
P. falciparum infected erythrocytes. Therefore, the inability of
spermidine to abolish Genz-644131 inhibition does not appear
to be due to the inability of the parasite to take up spermidine.
Genz-644131 shows improved in vivo cellular toxicity against
different T. brucei parasite strains (Bacchi et al., 2009; Barker
et al., 2009). When this compound was tested in a murine malaria
model for in vivo antimalarial activity, Genz-644131 signiﬁcantly
(P < 0.001) reduced P. berghei parasitaemia by 89% when dosed in
the Peters model for 4 days at 100 mg/kg/day. Animals dosed
with 20 mg/kg/day showed a 37% (P = 0.002) reduction. However,
in no case was there sterile cure, as all animals had detectable
parasitaemia levels on day 4 (Supplemental data S3). This may
be due to the cytostatic effect described above.
The evidence provided does however not exclude the possibil-
ity of off target effects of Genz-644131 on P. falciparum parasitesincluding its binding to purine deaminases and polyamine oxi-
dases as observed for MDL73811 (Hirth et al., 2009), particularly
to P. falciparum adenosine deaminases (Reyes et al., 1982) and
erythrocytic polyamine oxidases (Byers et al., 1992). However,
Genz-644131 (at 2 IC50) arrested parasite development in a
stage-speciﬁc manner during the trophozoite stages (18–26 h
post invasion), as previously described for MDL73811 (Wright
et al., 1991). This corresponds to the requirement of polyamines
due to the stage-speciﬁc expression of PfAdoMetDC/ODC
(18–30 h post-invasion) during the trophozoite stage of the
asexual cycle (van Brummelen et al., 2008). The parasite arrested
temporal phenotype induced by Genz-644131 therefore corre-
sponds to the expression proﬁle of PfAdoMetDC in the parasite
as the target for this compound.
Another explanation for the relatively poor activity of Genz-
644131 against intraerythrocytic P. falciparum parasites may be
due to the poor membrane permeability of the compound itself,
as low membrane permeability was previously shown to be the
only inferior in vitro ADME characteristic of the MDL73811 deriva-
tives (Barker et al., 2009). Additionally, for any compound to access
the intraerythrocytic P. falciparum parasites, they would need to
cross the parasite plasma membrane (PPM), parasitophorous vacu-
olar membrane (PVM) and erythrocyte membrane (Lingelbach and
Joiner, 1998). Extracellular T. brucei parasites are surrounded by
only a single plasma membrane (Vennerstrom et al., 2004; Orhan
et al., 2006) and cannot synthesise purines de novo, and therefore
have to acquire host purines (Hassan and Coombs, 1988). Adeno-
sine, of which MDL73811 is a structural analogue, is actively trans-
ported into T. brucei parasites by the T. brucei nucleotide
transporter 1 (TbNT1) (de Koning et al., 2005) and the T. brucei ami-
nopurine transporter (TbAT1 or P2). The latter transporter has been
conﬁrmed to actively transport MDL73811 (Goldberg et al., 1997;
Maser et al., 1999), which could explain the low nanomolar
in vitro IC50 values of MDL73811 in these parasites. As in T. brucei,
Plasmodium parasites also do not synthesise purines de novo and
has to recruit exogenous purines from the host (Downie et al.,
2008). In contrast to T. brucei, multiple transport mechanisms
enable the uptake of purines into intraerythrocytic P. falciparum
parasites including host purine transporters (Quashie et al., 2008)
as well as parasite derived transporters, PfNT1 and PfNT4 localised
in the PPM (Carter et al., 2000; Parker et al., 2000). Although the
latter are low-afﬁnity transporters (Downie et al., 2008), their
ability to transport MDL73811 and derivatives needs further
investigation.
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solution for the challenges facing malaria chemotherapeutics, since
it has the potential to mediate sustained, targeted drug release
thereby increasing the drug plasma half-life, lowering dosage
requirements and reducing drug toxicity (Maurer et al., 2011).
Additionally, lipid-based nanovectors has been shown to eliminate
off-target effects by delivery to speciﬁc targeted cells, thereby
improving the therapeutic efﬁcacy of the compound (Forrest and
Kwon, 2008). This makes lipid based nanovector drug delivery sys-
tems ideal for treatment of intracellular pathogens (Alving, 1986;
Armstead and Bingyun, 2011; Maurer et al., 2011). Previous encap-
sulations of chloroquine (Urbán et al., 2011a) and fosmidomycin
(Urbán et al., 2011b) resulted in a 10- and 7.5-fold decrease in
the in vitro IC50 values of these compounds.
To investigate possible enhancement of the uptake of Genz-
644131 into intraerythrocytic P. falciparum parasites, the
compound was incorporated into two nanovector drug delivery
systems: Pheroid

and immunoliposomes (Steyn et al., 2011; Urbá-
n et al., 2011a). The Pheroid

system is a nanovector carrier devel-
oped from a submicron micellular emulsion formulation, typically
ranging in size from 80 to 300 nm (Steyn et al., 2011). These micel-
lular structures can be manipulated in terms of structure, size and
morphology to enhance the solubility properties of intended com-
pounds, by entrapment and delivery of compounds across cellular
membranes (Steyn et al., 2011). Liposomes are synthetic lipid
bilayers of up to 200 nm that have the ability to increase drug bio-
availability by encapsulating compounds into the hydrophilic core
of the lipid bilayer system. Moreover, the liposomal preparations
were orientated with half anti-glycophorin A antibodies, speciﬁc
for intraerythrocytic P. falciparum parasites, enhancing the selec-
tivity of Genz-644131 to the parasite (Urbán et al., 2011a). Here,
the 32-fold decrease observed in the in vitro IC50 of immunolipo-
some encapsulated Genz-644131 against intraerythrocytic P. falci-
parum parasites suggests that the uptake of Genz-644131 by itself
into intracellular P. falciparum parasites is restricted. However, the
activity of compounds can be improved by either enhancing the
chemical pharmacokinetic properties through medicinal chemis-
try, or encapsulating the compound into drug delivery systems.
Although the Genz-644131 immunoliposome combination has
not been tested in vivo, other immunoliposomal drug suspensions
tested against murine mice infections improved the pharmacoki-
netic proﬁles of the drugs tested (Owais et al., 1995; Agrawal
and Gupta, 2000). Encapsulation of Genz-644131 with immuno-
liposomes may also reduce non-speciﬁc off-target effects and in
an sustainable release of the drug to prolong its plasma half-life.
The combination of Genz-644131 with a novel nanovector drug
delivery system therefore provides the most promising result ob-
tained thus far with this nanovector delivery system against intra-
erythrocytic P. falciparum parasites in vitro, and could be evaluated
in novel antimalarial drug development.
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